search
Back to results

Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
SHR0532
SHR placebo
Hydrochlorothiazide 25 mg
Sponsored by
Jiangsu HengRui Medicine Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Males or females between 18 to 65 years old
  • Diagnosis of mild hypertension
  • 18.5 kg/m2≤Body mass index (BMI) ≤35 kg/m^2
  • Understand the study procedure and method, willing to participate the study and Informed consent form (ICF) signed in writing

Exclusion Criteria:

  • History of significant drug allergy or allergic diseases (asthma, urticaria, eczematous dermatitis), or known allergy to anti hypertension drugs
  • Anti-hypertensive drugs were taken within 1 month before screening
  • History or at present patient has orthostatic hypotension
  • History or at screening Participant has plasma sodium lower than 135mmol/L
  • History or at screening visit/baseline patient has elevated serum uric acid (serum uric acid higher than ULN)
  • Patients with type 1 diabetes mellitus need insulin therapy or poor blood glucose control (HbA1c > 9%, or oral anti diabetic drug dosage is not stable within 4 weeks before screening)
  • History of arrhythmia or patient has clinically significant abnormalities of 12-lead ECG or prolonged corrected QT (QTc) interval (male > 450ms; female > 460ms) at screening visit
  • History of New York Heart Association (NYHA) Definition II-IV Heart Failure
  • Severe cardiovascular diseases occurred within 6 months before screening, including ischemic heart disease, peripheral vascular disease, significant ventricular tachycardia, atrial fibrillation, atrial flutter or other serious arrhythmias, hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, aortic or mitral valve disease of great hemodynamic significance, and severe cerebrovascular disease
  • History of percutaneous intervention (PCI) or coronary artery bypass graft (CABG)
  • History or active stroke, chronic seizures, or major neurological disorder
  • History of osteoporosis, nephrocalcinosis, nephrolithiasis or hypercalciuria
  • History or active malignant neoplastic disease. Exceptions: malignancies which have been successfully treated and non-recurrence >10 years prior to the screening visit
  • Patients having following diseases may affect drug absorption, distribution, metabolism and excretion:

Gastrointestinal diseases such as irritable bowel syndrome, inflammatory bowel diseases including ulcerative colitis, Crohn's disease, malabsorption syndrome, microbial dysbiosis, intestinal infection; History of gastrointestinal operations, such as gastric resection and bypass, small intestinal resection and colonic resection which may affect drug absorption

  • History of acute or chronic kidney diseases
  • Dehydration or volume-depletion
  • Clinically significant chronic or acute infectious diseases occur within 2 weeks before the start of the study (enrolment);
  • Major surgery within 3 months before dosing
  • Donation of blood/plasma within 1 month before dosing or blood/plasma (≥400 mL) within 3 months before dosing
  • Unstable or severe urinary, digestive, psychiatric, neural, hematological and other diseases, or lab abnormalities, the investigators determine that participants in the study will be at unacceptable risk

Taking or having the following medication history:

  • Participant need taking Cytochrome P450 3A4 (CYP3A4) inhibitors (such as ritonavir, indinavir, nelfinavir, erythromycin, telithromycin, clarithromycin, chloramphenicol, fluconazole, ketoconazole, itraconazole, verapamil or diltiazem) as well as strong/moderate CYP3A4 inducers (such as phenytoin, carbamazepine, oxcarbazepine, phenobarbital, efavirenz, nevirapine, rifampicin, modafinil, cyproterone or progestin) at least 2 weeks or 5 half-lives prior to administration of the initial dose of study drug until the post study visit
  • Use of non-steroidal anti-inflammatory drugs (NSAIDs) at least 2 weeks before 1st dose of study drug until the post study visit
  • use of systemic glucocorticoid therapy

Any laboratory examination result meet the following criteria at screening/baseline:

  • Serum potassium < 3.5mmol/L or > 5.5mmol/L
  • Serum creatinine more than ULN, Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 2.0 x ULN or total bilirubin more than 1.5 x ULN at screening/baseline visit
  • Creatinine kinase (CK) more than 3.0 x ULN at screening/baseline visit;
  • Clinically significant abnormalities of coagulation and thyroid function
  • HbsAg and Hepatitis B Virus (HBV)-DNA> 1000 cps/ml, Hepatitis C Virus Antibody (HCVAb), syphilis and HIV antibodies were positive at screening visit
  • Serum pregnant test positive at screening/baseline visit

Sites / Locations

  • The second Affiliated Hospital Zhejiang University School of Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Placebo Comparator

Active Comparator

Arm Label

SHR0532 tablet

SHR0532 placebo

Hydrochlorothiazide

Arm Description

up to 3 cohorts of subjects will receive multiple dose of oral tablets

up to 3 cohorts of subjects will receive multiple dose of oral SHR0532 placebo

up to 3 cohorts of subjects will receive multiple dose of oral Hydrochlorothiazide 25mg

Outcomes

Primary Outcome Measures

Adverse Events(AEs) and Serious Adverse Events (SAEs)
Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events, incidence of drug related adverse events (safety and tolrability)

Secondary Outcome Measures

Change From Baseline in Clinic Systolic Blood Pressure (SBP) and Clinic Diastolic Blood Pressure (DBP)
Each subject has their office blood pressure every day of each treatment period (total of 28 days of treatment). The difference between baseline and D28 of each office BP value are calculated and recorded.
Change from baseline in 24h Urine sodium
Urine sodium (Na) levels were measured over 24-hours and different time period of 24 hours on Day -1 (baseline) and on Day 1to Day 7, Day28 to Day 32. The total amount of Na excreted in the Urine for Day-1 (baseline) and Day1 to Day 7, Day 28 to Day 32 were calculated and recorded and the difference between the 2 values are recorded.
Change from baseline in 24h Urine Volume
Urine Volume were measured over 24-hours and different time period of 24 hours on Day -1 (baseline) and on Day 1to Day 7, Day28 to Day 32.The total amount of Urine excreted for Day-1 (baseline) and Day1 to Day 7, Day 28 to Day 32 were calculated and recorded and the difference between the 2 values are recorded.

Full Information

First Posted
May 28, 2019
Last Updated
October 8, 2021
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT03971929
Brief Title
Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension
Official Title
A Phase I, Randomized, Double-Blind, Placebo-hydrochlorothiazide Parallel Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Efficacy of SHR 0532 Oral Tablets in Mild Hypertension Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
May 2019
Overall Recruitment Status
Completed
Study Start Date
July 31, 2019 (Actual)
Primary Completion Date
September 3, 2020 (Actual)
Study Completion Date
September 3, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Jiangsu HengRui Medicine Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The study is being conducted to evaluate the safety and efficacy and Pharmacokinetics/Pharmacodynamics of SHR0532 in subjects with mild hypertension for 4 weeks.
Detailed Description
This is a randomized, double-blind, multiple ascending dose, placebo- and Hydrochlorothiazide-controlled study to evaluate the safety and tolerability, Pharmacokinetics and Pharmacodynamics and effect on blood pressure of SHR0532 tablets in patients with mild hypertension.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
36 (Actual)

8. Arms, Groups, and Interventions

Arm Title
SHR0532 tablet
Arm Type
Experimental
Arm Description
up to 3 cohorts of subjects will receive multiple dose of oral tablets
Arm Title
SHR0532 placebo
Arm Type
Placebo Comparator
Arm Description
up to 3 cohorts of subjects will receive multiple dose of oral SHR0532 placebo
Arm Title
Hydrochlorothiazide
Arm Type
Active Comparator
Arm Description
up to 3 cohorts of subjects will receive multiple dose of oral Hydrochlorothiazide 25mg
Intervention Type
Drug
Intervention Name(s)
SHR0532
Intervention Description
once daily(QD) for 4weeks
Intervention Type
Drug
Intervention Name(s)
SHR placebo
Intervention Description
once daily(QD) for 4weeks
Intervention Type
Drug
Intervention Name(s)
Hydrochlorothiazide 25 mg
Intervention Description
once daily(QD) for 4weeks
Primary Outcome Measure Information:
Title
Adverse Events(AEs) and Serious Adverse Events (SAEs)
Description
Incidence of AEs and SAEs, incidence of Treatment-Emergent Adverse Events, incidence of drug related adverse events (safety and tolrability)
Time Frame
from informed consent form signature to the end of the study (up to 2 months)
Secondary Outcome Measure Information:
Title
Change From Baseline in Clinic Systolic Blood Pressure (SBP) and Clinic Diastolic Blood Pressure (DBP)
Description
Each subject has their office blood pressure every day of each treatment period (total of 28 days of treatment). The difference between baseline and D28 of each office BP value are calculated and recorded.
Time Frame
Baseline to end of the study (up to 32 days)
Title
Change from baseline in 24h Urine sodium
Description
Urine sodium (Na) levels were measured over 24-hours and different time period of 24 hours on Day -1 (baseline) and on Day 1to Day 7, Day28 to Day 32. The total amount of Na excreted in the Urine for Day-1 (baseline) and Day1 to Day 7, Day 28 to Day 32 were calculated and recorded and the difference between the 2 values are recorded.
Time Frame
from baseline to Day 8; from D28 to D32 (up to 32 days)
Title
Change from baseline in 24h Urine Volume
Description
Urine Volume were measured over 24-hours and different time period of 24 hours on Day -1 (baseline) and on Day 1to Day 7, Day28 to Day 32.The total amount of Urine excreted for Day-1 (baseline) and Day1 to Day 7, Day 28 to Day 32 were calculated and recorded and the difference between the 2 values are recorded.
Time Frame
from baseline to Day 8; from D28 to D32 (up to 32 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Males or females between 18 to 65 years old Diagnosis of mild hypertension 18.5 kg/m2≤Body mass index (BMI) ≤35 kg/m^2 Understand the study procedure and method, willing to participate the study and Informed consent form (ICF) signed in writing Exclusion Criteria: History of significant drug allergy or allergic diseases (asthma, urticaria, eczematous dermatitis), or known allergy to anti hypertension drugs Anti-hypertensive drugs were taken within 1 month before screening History or at present patient has orthostatic hypotension History or at screening Participant has plasma sodium lower than 135mmol/L History or at screening visit/baseline patient has elevated serum uric acid (serum uric acid higher than ULN) Patients with type 1 diabetes mellitus need insulin therapy or poor blood glucose control (HbA1c > 9%, or oral anti diabetic drug dosage is not stable within 4 weeks before screening) History of arrhythmia or patient has clinically significant abnormalities of 12-lead ECG or prolonged corrected QT (QTc) interval (male > 450ms; female > 460ms) at screening visit History of New York Heart Association (NYHA) Definition II-IV Heart Failure Severe cardiovascular diseases occurred within 6 months before screening, including ischemic heart disease, peripheral vascular disease, significant ventricular tachycardia, atrial fibrillation, atrial flutter or other serious arrhythmias, hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, aortic or mitral valve disease of great hemodynamic significance, and severe cerebrovascular disease History of percutaneous intervention (PCI) or coronary artery bypass graft (CABG) History or active stroke, chronic seizures, or major neurological disorder History of osteoporosis, nephrocalcinosis, nephrolithiasis or hypercalciuria History or active malignant neoplastic disease. Exceptions: malignancies which have been successfully treated and non-recurrence >10 years prior to the screening visit Patients having following diseases may affect drug absorption, distribution, metabolism and excretion: Gastrointestinal diseases such as irritable bowel syndrome, inflammatory bowel diseases including ulcerative colitis, Crohn's disease, malabsorption syndrome, microbial dysbiosis, intestinal infection; History of gastrointestinal operations, such as gastric resection and bypass, small intestinal resection and colonic resection which may affect drug absorption History of acute or chronic kidney diseases Dehydration or volume-depletion Clinically significant chronic or acute infectious diseases occur within 2 weeks before the start of the study (enrolment); Major surgery within 3 months before dosing Donation of blood/plasma within 1 month before dosing or blood/plasma (≥400 mL) within 3 months before dosing Unstable or severe urinary, digestive, psychiatric, neural, hematological and other diseases, or lab abnormalities, the investigators determine that participants in the study will be at unacceptable risk Taking or having the following medication history: Participant need taking Cytochrome P450 3A4 (CYP3A4) inhibitors (such as ritonavir, indinavir, nelfinavir, erythromycin, telithromycin, clarithromycin, chloramphenicol, fluconazole, ketoconazole, itraconazole, verapamil or diltiazem) as well as strong/moderate CYP3A4 inducers (such as phenytoin, carbamazepine, oxcarbazepine, phenobarbital, efavirenz, nevirapine, rifampicin, modafinil, cyproterone or progestin) at least 2 weeks or 5 half-lives prior to administration of the initial dose of study drug until the post study visit Use of non-steroidal anti-inflammatory drugs (NSAIDs) at least 2 weeks before 1st dose of study drug until the post study visit use of systemic glucocorticoid therapy Any laboratory examination result meet the following criteria at screening/baseline: Serum potassium < 3.5mmol/L or > 5.5mmol/L Serum creatinine more than ULN, Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 2.0 x ULN or total bilirubin more than 1.5 x ULN at screening/baseline visit Creatinine kinase (CK) more than 3.0 x ULN at screening/baseline visit; Clinically significant abnormalities of coagulation and thyroid function HbsAg and Hepatitis B Virus (HBV)-DNA> 1000 cps/ml, Hepatitis C Virus Antibody (HCVAb), syphilis and HIV antibodies were positive at screening visit Serum pregnant test positive at screening/baseline visit
Facility Information:
Facility Name
The second Affiliated Hospital Zhejiang University School of Medicine
City
Hangzhou
State/Province
Hangzhou
ZIP/Postal Code
310009
Country
China

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Safety and Effect Study of SHR0532 (Drug Code) Tablets in Patients With Mild Hypertension

We'll reach out to this number within 24 hrs